Area of research
Epidemiology · Hepatology
Research interest
Research focused on Placebo and Double blind, with related work in Nonalcoholic steatohepatitis, Fibrosis, Insulin resistance. Notable publications include 'Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD', 'Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study', and 'Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD'.
Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD
Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD
Chiglitazar in MASLD with hypertriglyceridemia and insulin resistance: A phase II, randomized, double-blind, placebo-controlled study
IDDF2025-ABS-0058 Longitudinal changes in fibrosis markers: monitoring stiffness/fibrosis progression and prognostic outcomes in metabolic dysfunction-associated steatotic liver disease
Vitamin E (300mg) Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Low Dose Vitamin E Versus Placebo in the Treatment of Nonalcoholic Steatohepatitis: A Double-Blind, Randomized, Placebo-Controlled Investigator-Initiated Trial